Vertex Pharmaceuticals target price raised to $660 from $558 by Scotiabank
VRTX•Scotiabank raised its target price for Vertex Pharmaceuticals to $660 from $558.
Related News
Tempus AI target price raised to $89 from $75
TEM•
Inspire Medical Systems, Inc.: Jefferies raises target price to $60 from $55
INSP•
Southside Bancshares publishes third-quarter 2026 earnings call transcript
SBSI•
JPMorgan raises Carlyle Group target price to $64 from $62
CG•
BofA Global Research raises Ares Management price objective to $164 from $156
ARES•